Erlotinib Unknown Status Phase 3 Trials for Lung Cancers Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00989690Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer